ReviewInflammatory bowel diseases2017
Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.
Review in Inflammatory bowel diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 5 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Impact of Age on Efficacy and Safety of Advanced Therapies During Induction in Ulcerative Colitis: An Individual Patient Data Pooled Analysis from Randomized Controlled Trials.Digestive diseases and sciences · 2026Pooled it
- Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Pooled it
- Assessing causality between inflammatory bowel diseases with frailty index and sarcopenia: a bidirectional Mendelian randomization study.European journal of medical research · 2024Pooled it
- Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis.BMC gastroenterology · 2022Pooled it
- Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.Techniques in coloproctology · 2020Guideline
- Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.Inflammatory bowel diseases · 2025Trial
- Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT.Alimentary pharmacology & therapeutics · 2019Trial
- Upadacitinib Is Safe and Effective in Older Adults: A Real-World Experience Comparing Safety and Efficacy in Younger Versus Older Adults with Inflammatory Bowel Disease.Digestive diseases and sciences · 2026Article
- Soluble mucosal addressin cell adhesion molecule 1 is a biomarker for pediatric ulcerative colitis.Molecular and cellular pediatrics · 2026Article
- Understanding Frailty in IBD: Implications for Clinical Outcomes and Multidisciplinary Care.Journal of clinical medicine · 2026Review
- MicroRNAs as novel therapeutic targets against inflammatory bowel disease through modulation of ferroptosis.Clinical and experimental medicine · 2026Review
- Effectiveness of the Crohn's Disease Exclusion Diet for the Treatment of Crohn's Disease in the Older-Adult Population: Real-World Experience.Digestive diseases (Basel, Switzerland) · 2026Article
- Gut Hormones and Inflammatory Bowel Disease.Biomolecules · 2025Review
- A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based study.The Lancet regional health. Europe · 2024Article
- Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.Journal of Crohn's & colitis · 2024Review
- Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.Journal of clinical medicine · 2024Article
- Burden of delirium on mortality and healthcare resource utilization in geriatric patients hospitalized for inflammatory bowel disease.Proceedings (Baylor University. Medical Center) · 2024Article
- Unraveling the fatigue puzzle: insights into the pathogenesis and management of IBD-related fatigue including the role of the gut-brain axis.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The population of older patients with inflammatory bowel disease (IBD) continues to grow, partly reflecting the aging global population in general. The debilitating effects of IBD compound age-related decrements in health and functional capacity, and make the medical management of older patients with Crohn's disease and ulcerative colitis distinctly challenging to clinicians. Here, we review the recent literature describing the pharmacologic management of IBD in this population, with focus on the safety, tolerability, and efficacy of common treatment options, such as steroids, immunomodulators, tumor necrosis factor-α antagonists, and integrin antagonists; surgical interventions in older patients are also discussed. Few studies have systematically and prospectively evaluated the clinical challenges in the medical management of IBD in this patient population, leaving a limited evidence base to which clinicians can turn to for guidance. Treatment patterns may thus be suboptimal. For example, prolonged steroid use in the elderly was found to be common, causing significant morbidity from side effects in a particularly vulnerable population. Finally, within the context of a limited evidence base, we discuss common treatment scenarios to define the parameters within which physicians can individualize care for older patients with IBD. Overall, older patients with IBD are at higher risk of adverse events and less treatment responsiveness compared with younger patients, underscoring the need for future studies to fully characterize appropriate treatment courses for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.